Stimulants in excessive daytime sleepiness

Sleep Medicine Clinics

Volumn 5, Issue 4, 2010, Pages 591-607

  Sakai, Noriaki ^a   Chikahisa, Sachiko ^a,b   Nishino, Seiji ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF TOKUSHIMA   (Japan)

Author keywords

Amphetamine; EDS; Methamphetamine; Methylphenidate; Modafinil; Narcolepsy

Indexed keywords

AMFEBUTAMONE; AMINEPTINE; AMPHETAMINE; ARMODAFINIL; ATOMOXETINE; CAFFEINE; CENTRAL STIMULANT AGENT; CLOMIPRAMINE; CYTOCHROME P450 2D6; DESIPRAMINE; DEXAMPHETAMINE; DEXMETHYLPHENIDATE; DOPAMINE; ETHINYLESTRADIOL; IMIPRAMINE; MAZINDOL; METHAMPHETAMINE; METHYLPHENIDATE; MODAFINIL; MONOAMINE OXIDASE INHIBITOR; NISOXETINE; NOMIFENSINE; NORADRENALIN; PARAXANTHINE; PEMOLINE; REBOXETINE; SELEGILINE; TRIAZOLAM; UNINDEXED DRUG; VANOXERINE; VESICULAR MONOAMINE TRANSPORTER 2;

ADRENERGIC TRANSMISSION; AMINO ACID SUBSTITUTION; ANGIONEUROTIC EDEMA; ANOREXIA; AROUSAL; ATTENTION DEFICIT DISORDER; CATAPLEXY; CATECHOLAMINERGIC SYSTEM; CLINICAL TRIAL; CONSTIPATION; DAYTIME SOMNOLENCE; DOPAMINERGIC SYSTEM; DRUG ABUSE; DRUG ACCUMULATION; DRUG ACTIVITY; DRUG CLEARANCE; DRUG HALF LIFE; DRUG INDICATION; DRUG MECHANISM; DRUG MISUSE; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG STRUCTURE; DRUG TARGETING; ELECTROENCEPHALOGRAPHY; FATIGUE; GASTROINTESTINAL SYMPTOM; HEADACHE; HEART PALPITATION; HUMAN; HYPERHIDROSIS; HYPERSOMNIA; HYPERTENSION; INSOMNIA; IRRITABILITY; MOOD CHANGE; MULTIPLE SCLEROSIS; NARCOLEPSY; NAUSEA; NERVOUSNESS; NEUROCHEMISTRY; NEUROPHARMACOLOGY; NEUROPHYSIOLOGY; PRESYNAPTIC POTENTIAL; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SLEEP; SLOW WAVE SLEEP; STOMACH ACID SECRETION; STRUCTURE ACTIVITY RELATION; SUBSTANTIA NIGRA; TREMOR; URINE RETENTION; URINE VOLUME; VOMITING; WAKEFULNESS; XEROSTOMIA;

EID: 78649346707     PISSN: 1556407X     EISSN: 15564088     Source Type: Journal    
DOI: 10.1016/j.jsmc.2010.08.009     Document Type: Review

References (79)

1. S.H. Snyder Drugs and the brain vol. 18 1986 Scientific American Library New York
2. J.D. Parkes Central nervous system stimulant drugs M. Thorpy, Handbook of sleep disorders 1990 Marcel Dekker New York 755
3. R.E. Yoss, and D.D. Daly Treatment of narcolepsy with ritalin Neurology 9 1959 171
4. C. Bradley, and M. Bowen Amphetamine (benzedrine) therapy of children's behavior disorders Am J Orthospychiatry 11 1941 92
5. T.F. Anders, and R.D. Ciaranello Pharmacologic treatment of minimal brain dysfunction syndrome J.D. Barchas, P.A. Berger, R.D. Ciaranello, Psychopharmacology: from theory to practice 1977 Oxford University Press New York 425
6. R.A. Glennon Psychoactive phaenylisopropylamines H.Y. Meltzer, Psychopharmacology: the third generation of progress 1987 Raven New York 1627
7. A. Hartmann, and J. Cravens Sleep: effect of d- and l-amphetamine in man and rat Psychopharmacology 50 1976 171
8. R. Kuczenski, and D.S. Segal Neurochemistry of amphetamine A.K. Cho, D.S. Segel, Psychopharmacology, toxicology and abuse 1994 Academic Press San Diego (CA) 81
9. S. Nishino, J. Mao, and R. Sampathkumaran Increased dopaminergic transmission mediates the wake-promoting effects of CNS stimulants Sleep Res Online 1 1998 49
10. S. Nishino, and E. Mignot Pharmacological aspects of human and canine narcolepsy Prog Neurobiol 52 1997 27
11. R. Kuczenski, D.S. Segal, and A. Cho Hippocampus norepinephrine, caudate dopamine and serotonin and behavioral responses to the stereoisomers of amphetamine and methamphetamine J Neurosci 15 1995 1308
12. T. Kanbayashi, S. Nishino, and K. Honda Differential effects of D-and L-amphetamine isomers on dopaminergic transmission: implication for the control of alertness in canine narcolepsy J Sleep Res 26 1997 383
13. J.P. Wisor, S. Nishino, and I. Sora Dopaminergic role in stimulant-induced wakefulness J Neurosci 21 2001 1787
14. A. Björklund, and O. Lindvall Dopamine-containing systems in the CNS A. Björklund, T. Hökfelt, Handbook of chemical neuroanatomy, classical transmitter in the CNS, part I vol. 2 1984 Elsevier Amsterdam 55
15. N. Nissbrandt, G. Engberg, and E. Pileblad The effects of GBR 12909, a dopamine re-uptake inhibitor, on monoaminergic neurotransmission in rat striatum, limbic forebrain, cortical hemispheres and substantia nigra Naunyn Schmiedebergs Arch Pharmacol 344 1991 16
16. K. Honda, J. Riehl, and E. Mignot Dopamine D3 agonists into the substantia nigra aggravate cataplexy but do not modify sleep Neuroreport 10 1999 3717
17. J. Lu, T.C. Jhou, and C.B. Saper Identification of wake-active dopaminergic neurons in the ventral periaqueductal gray matter J Neurosci 26 2006 193
18. J.M. Monti, and D. Monti The involvement of dopamine in the modulation of sleep and waking Sleep Med Rev 11 2007 113
19. Piscopo A. The impact of prescription drug diversion control systems on medical practice and patient care. In National Institute on Drug Abuse Technical Review Meeting. Bethesda, MD, May 30-June 1, 1991.
20. L. de Lecea, B.E. Jones, and B. Boutrel Addiction and arousal: alternative roles of hypothalamic peptides J Neurosci 26 2006 10372
21. G.F. Koob, and E.J. Nestler The neurobiology of drug addiction J Neuropsychiatry Clin Neurosci 9 1997 482
22. C. Drouin, L. Darracq, and F. Trovero Alpha1b-adrenergic receptors control locomotor and rewarding effects of psychostimulants and opiates J Neurosci 22 2002 2873
23. L. Salomon, C. Lanteri, and G. Godeheu Paradoxical constitutive behavioral sensitization to amphetamine in mice lacking 5-HT2A receptors Psychopharmacology (Berl) 194 2007 11
24. J.S. Markowitz, and K.S. Patrick Pharmacokinetic and pharmacodynamic drug interactions in the treatment of attention-deficit hyperactivity disorder Clin Pharmacokinet 40 2001 753
25. P. Robertson Jr., and E.T. Hellriegel Clinical pharmacokinetic profile of modafinil Clin Pharmacokinet 42 2003 123
26. E. Mignot, S. Nishino, and C. Guilleminault Modafinil binds to the dopamine uptake carrier site with low affinity Sleep 17 1994 436
27. S. Nishino, and M. Okuro Armodafinil for excessive daytime sleepiness Drugs Today (Barc) 44 2008 395
28. W.M. Qu, Z.L. Huang, and X.H. Xu Dopaminergic D1 and D2 receptors are essential for the arousal effect of modafinil J Neurosci 28 2008 8462
29. J.P. Wisor, and K.S. Eriksson Dopaminergic-adrenergic interactions in the wake promoting mechanism of modafinil Neuroscience 132 2005 1027
30. R. Parmentier, C. Anaclet, and C. Guhennec The brain H3-receptor as a novel therapeutic target for vigilance and sleep-wake disorders Biochem Pharmacol 73 2007 1157
31. B.K. Madras, Z. Xie, and Z. Lin Modafinil occupies dopamine and norepinephrine transporters in vivo and modulates the transporters and trace amine activity in vitro J Pharmacol Exp Ther 319 2006 561
32. N.D. Volkow, J.S. Fowler, and J. Logan Effects of modafinil on dopamine and dopamine transporters in the male human brain: clinical implications JAMA 301 2009 1148
33. H. Bastuji, and M. Jouvet Successful treatment of idiopathic hypersomnia and narcolepsy with modafinil Prog Neuropsychopharmacol Biol Psychiatry 12 1988 695
34. A. Besset, M. Tafti, and E. Villemine Effect du modafinil (300 mg) sur le sommeil, la somnolence et la vigilance du narcoleptique Neurophysiol Clin 23 1993 47
35. D.B. Boivin, J. Montplaisir, and D. Petit Effect of modafinil on symptomatology of human narcolepsy Clin Neuropharmacol 16 1993 46
36. Randomized trial of modafinil for the treatment of pathological somnolence in narcolepsy. US Modafinil in Narcolepsy Multicenter Study Group Ann Neurol 43 1998 88
37. J. Shelton, S. Nishino, and J. Vaught Comparative effects of modafinil and amphetamine on daytime sleepiness and cataplexy of narcoleptic dogs Sleep 18 1995 817
38. J. Fry, and Group TMs A new alternative in the pharmacologic management of somnolence: a phase III study of modafinil in narcolepsy Ann Neurol 40 1996 493
39. LaGarde D. Sustained/Continuous Operations Subgroup of the Department of Defense Human Factors Engineering Technical Group: program summary and abstracts from the 9th semiannual meeting. Pensacola, FL, July 11-12, 1989. p. 90.
40. L.H. Gold, and R.L. Balster Evaluation of the cocaine-like discriminative stimulus effects and reinforcing effects of modafinil Psychopharmacology (Berl) 126 1996 286
41. J. Brun, G. Chamba, and Y. Khalfallah Effect of modafinil on plasma melatonin, cortisol and growth hormone rhythms, rectal temperature and performance in healthy subjects during a 36 h sleep deprivation J Sleep Res 7 1998 105
42. D.M. Edgar, W.F. Seidel, and P. Contreras Modafinil promotes EEG wake without intensifying motor activity in the rat Can J Physiol Pharmacol 72 S1 1994 362
43. D.M. Edgar, and W.F. Seidel Modafinil induces wakefulness without intensifying motor activity or subsequent rebound hypersomnolence in the rat J Pharmacol Exp Ther 283 1997 757
44. J.D. Parkes, and M. Shachter Mazindol in the treatment of narcolepsy Acta Neurol Scand 60 1979 250
45. S. Iijima, Y. Sugita, and Y. Teshima Therapeutic effects of mazindol on narcolepsy Sleep 9 1986 265
46. D.B. Rye, B. Dihenia, and D.L. Bliwise Reversal of atypical depression, sleepiness, and REM-sleep propensity in narcolepsy with bupropion Depress Anxiety 7 1998 92
47. L.I. Golbe Deprenyl as symptomatic therapy in Parkinson's disease Clin Neuropharmacol 11 1988 387
48. G.P. Reynolds, J.D. Elsworth, and K. Blau Deprenyl is metabolized to methamphetamine and amphetamine in man Br J Clin Pharmacol 6 1978 542
49. S. Nishino, J. Arrigoni, and T. Kanbayashi Comparative effects of MAO-A and MAO-B selective inhibitors on canine cataplexy J Sleep Res 25 1996 315
50. C. Hublin, M. Partinen, and E.H. Heinonen Selegiline in the treatment of narcolepsy Neurology 44 1994 2095
51. G. Mayer, E. Meier, and K. Hephata Selegiline hydrochloride in narcolepsy: a double-blind placebo-controlled study Clin Neuropharmacol 18 1995 306
52. R.L. Findling Evolution of the treatment of attention-deficit/ hyperactivity disorder in children: a review Clin Ther 30 2008 942
53. R. Bart Sangal, J.M. Sangal, and K. Thorp Atomoxetine improves sleepiness and global severity of illness but not the respiratory disturbance index in mild to moderate obstructive sleep apnea with sleepiness Sleep Med 9 2008 506
54. O. Larrosa, Y. de la Llave, and S. Bario Stimulant and anticataplectic effects of reboxetine in patients with narcolepsy: a pilot study Sleep 24 2001 282
55. T.R. Rall Central nervous system stimulants A.G. Gilman, L.S. Goodman, T.W. Rall, The pharmacological basis of therapeutics 7th edition 1985 Pergamon Press New York 345
56. T. Porkka-Heiskanen, R.E. Strecker, and M. Thakkar Adenosine: a mediator of the sleep-inducing effects of prolonged wakefulness Science 276 1997 1265
57. Z.L. Huang, W.M. Qu, and N. Eguchi Adenosine A2A, but not A1, receptors mediate the arousal effect of caffeine Nat Neurosci 8 2005 858
58. M. Okuro, N. Fujiki, and N. Kotorii Effects of paraxanthine and caffeine on sleep, locomotor activity and body temperature in orexin/ataxin-3 transgenic narcoleptic mice Sleep 33 7 2010 930 942
59. M. Mieda, J.T. Willie, and J. Hara Orexin peptides prevent cataplexy and improve wakefulness in an orexin neuron-ablated model of narcolepsy in mice Proc Natl Acad Sci U S A 101 2004 4649
60. K. Mishima, N. Fujiki, and Y. Yoshida Hypocretin receptor expression in canine and murine narcolepsy models and in hypocretin-ligand deficient human narcolepsy Sleep 31 2008 1119
61. N. Fujiki, B. Ripley, and Y. Yoshida Effects of IV and ICV hypocretin-1 (orexin A) in hypocretin receptor-2 gene mutated narcoleptic dogs and IV hypocretin-1 replacement therapy in a hypocretin ligand deficient narcoleptic dog Sleep 6 2003 953
62. S.J. Schatzberg, J. Barrett, and K.L. Cutter Case study: effect of hypocretin replacement therapy in a 3-year-old Weimeraner with narcolepsy J Vet Intern Med 18 2004 586
63. S. Nishino, N. Fujiki, and B. Ripley Decreased brain histamine contents in hypocretin/orexin receptor-2 mutated narcoleptic dogs Neurosci Lett 313 2001 125
64. T. Kanbayashi, T. Kodama, and H. Kondo CSF histamine contents in narcolepsy, idiopathic hypersomnia and obstructive sleep apnea syndrome Sleep 32 2009 181
65. S. Nishino, E. Sakurai, and S. Nevsimalova Decreased CSF histamine in narcolepsy with and without low CSF hypocretin-1 in comparison to healthy controls Sleep 32 2009 175
66. Z.L. Huang, W.M. Qu, and W.D. Li Arousal effect of orexin A depends on activation of the histaminergic system Proc Natl Acad Sci U S A 98 2001 9965
67. J.S. Lin, K. Sakai, and G. Vanni-Mercier Involvement of histaminergic neurons in arousal mechanisms demonstrated with H3-receptor ligands in the cat Brain Res 523 1990 325
68. T. Shiba, N. Fujiki, and J. Wisor Wake promoting effects of thioperamide, a histamine H3 antagonist in orexin/ataxin-3 narcoleptic mice Sleep 27 Suppl 2004 A241
69. S. Nishino, J. Arrigoni, and J. Shelton Effects of thyrotropin-releasing hormone and its analogs on daytime sleepiness and cataplexy in canine narcolepsy J Neurosci 17 1997 6401
70. J. Riehl, K. Honda, and M. Kwan Chronic oral administration of CG-3703, a thyrotropin releasing hormone analog, increases wake and decreases cataplexy in canine narcolepsy Neuropsychopharmacology 23 2000 34
71. C. Broberger, and D.A. McCormick Excitatory effects of thyrotropin-releasing hormone in the thalamus J Neurosci 25 2005 1664
72. J.A. Gonzalez, E. Horjales-Araujo, and L. Fugger Stimulation of orexin/hypocretin neurones by thyrotropin-releasing hormone J Physiol 587 2009 1179
73. J. Hara, D. Gerashchenko, and J.P. Wisor Thyrotropin-releasing hormone increases behavioral arousal through modulation of hypocretin/orexin neurons J Neurosci 29 2009 3705
74. R. Parmentier, S. Kolbaev, and B.P. Klyuch Excitation of histaminergic tuberomammillary neurons by thyrotropin-releasing hormone J Neurosci 29 2009 4471
75. T.L. Stanton, A. Winokur, and A.L. Beckman Seasonal variation in thyrotropin-releasing hormone (TRH) content of different brain regions and the pineal in the mammalian hibernator, Citellus lateralis Regul Pept 3 1982 135
76. L.J. Porrino, J.B. Daunais, and G.A. Rogers Facilitation of task performance and removal of the effects of sleep deprivation by an ampakine (C×717) in nonhuman primates PLoS Biol 3 2005 e299
77. D.T. Joo, Z. Xiong, and J.F. MacDonald Blockade of glutamate receptors and barbiturate anesthesia: increased sensitivity to pentobarbital-induced anesthesia despite reduced inhibition of AMPA receptors in GluR2 null mutant mice Anesthesiology 91 1999 1329
78. H.W. Steenland, S.S. Kim, and M. Zhuo GluR3 subunit regulates sleep, breathing and seizure generation Eur J Neurosci 27 2008 1166
79. G. Tononi, and C. Cirelli Sleep function and synaptic homeostasis Sleep Med Rev 10 2006 49